Paper Details

  1. Home
  2. Paper Details

Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study.

Author: BolisG, BortolozziG, CarinelliG, D'IncalciM, GramelliniF, MangioniC, MorascaL

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study of 74 patients with ovarian cancer found that the combination of CTX and ADM was associated with a higher response rate (52%) compared to CTX alone (42%). However, the combination treatment was associated with more side effects. There was no significant difference in survival between the two groups.
Paper Details　
Original Abstract of the Article :
After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median surviva...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF00254034

データ提供：米国国立医学図書館（NLM）

Treating Advanced Ovarian Cancer: A Comparative Study of Chemotherapy Regimens

Ovarian cancer is a serious disease, and finding effective treatments is a critical challenge. This research compares the effectiveness of two chemotherapy regimens for advanced ovarian cancer: low-dose cyclophosphamide and adriamycin plus cyclophosphamide.

The researchers found that both regimens resulted in similar response rates and survival times. However, the combination treatment with adriamycin plus cyclophosphamide was associated with a higher incidence of side effects. This suggests that low-dose cyclophosphamide may offer a less toxic alternative for treating advanced ovarian cancer.

Navigating the Chemotherapy Desert: Choosing the Right Path

This research provides valuable insights into treatment options for advanced ovarian cancer. The study's findings highlight the need for careful consideration of both efficacy and toxicity when selecting chemotherapy regimens. This emphasizes the importance of individualizing treatment plans based on patient factors and potential risks and benefits.

Dr.Camel's Conclusion

Ovarian cancer is a challenging desert to traverse, with many treatment options and potential side effects. This research helps us navigate this complex landscape, providing valuable insights into the effectiveness and safety of different chemotherapy regimens. As we continue to explore new approaches, our goal is to find the most effective and least burdensome treatment strategies to help patients overcome this challenging disease.

Date :
  1. Date Completed 1980-09-28
  2. Date Revised 2019-08-30
Further Info :

Pubmed ID

7389058

DOI: Digital Object Identifier

10.1007/BF00254034

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.